Cisplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one chemotherapy drug with radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving cisplatin and etoposide together with radiation therapy works in treating patients with limited-stage small cell lung cancer.
Checked against the public recordLast updated Dec 22, 2017 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- Radiation Therapy Oncology Group
- Interventions being studied
- Drug: Cisplatin; Drug: Etoposide; Radiation: Radiation therapy
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed small cell carcinoma of the lung by fine needle aspiration biopsy or two positive sputa * Must have limited disease * Stage I, II, IIIA, or IIIB * Confined to 1 hemithorax, but excluding the following: * T4 tumor based on malignant pleural effusion * N3 disease based on contralateral hilar or contralateral supraclavicular involvement * No pericardial or pleural effusions on chest x-ray (regardless of cytology) * Measurable or evaluable disease * Tumor must be able to be encompassed by limited radiotherapy fields without significantly compromising pulmonary function * No prior complete tumor resection PATIENT CHARACTERISTICS: Age * 18 to 100 Performance status * Zubrod 0-1 Life expectancy * Not specified Hematopoietic * Absolute granulocyte count at least 1,500/mm\^3 * Platelet count at least 150,000/mm\^3 Hepatic * Bilirubin no greater than 1.5 mg/dL Renal * Creatinine no greater than 1.5 mg/dL Cardiovascular * No myocardial infarction within the past 6 months * No symptomatic heart disease Pulmonary * No chronic obstructive pulmonary disease with Forced Expiratory Volume (FEV)-1 no greater than 0.8 liter * No uncontrolled bronchospasm in the unaffected lung Other * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * Available for follow-up * No other malignancy within the past 2 years except curatively treated basal cell or squamous cell skin cancer or non-invasive in situ malignancies * No other concurrent serious medical illness * No uncontrolled psychiatric illness * No chronic alcohol or drug abuse PRIOR CONCURRENT THERAPY: Biologic therapy * Not specified Chemotherapy * No prior chemotherapy Endocrine therapy * Not specified Radiotherapy * No prior radiotherapy to the chest or other area containing a large amount of bone marrow (e.g., more than 75% of pelvic bone) Surgery * See Disease Characteristics
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Comprehensive Cancer Center at University of Alabama at BirminghamBirmingham, Alabama
- Eden Medical CenterCastro Valley, California
- Saint Rose HospitalHayward, California
- Highland General Hospital at St. George's University School of MedicineOakland, California
- Alta Bates Summit Medical Center - Summit CampusOakland, California
- CCOP - Bay Area Tumor InstituteOakland, California
- Valley Care Medical CenterPleasanton, California
- Robert and Beverly Lewis Family Cancer Care Center at Pomona Valley Hospital Medical CenterPomona, California
- J.C. Robinson, M.D. Regional Cancer CenterSan Pablo, California
- Curtis & Elizabeth Anderson Cancer Institute at Memorial Health University Medical CenterSavannah, Georgia
- St. Joseph Medical CenterBloomington, Illinois
- Graham HospitalCanton, Illinois
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Dec 22, 2017. Always confirm current availability with the study team.